Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
Sehhoon ParkDongryul OhYoon-La ChoiSang Ah ChiKyunga KimMyung-Ju AhnJong-Mu SunPublished in: Cancer (2022)
Durvalumab and tremelimumab with definitive CCRT had promising efficacy in patients with locally advanced ESCC. In addition, PD-L1 expression had strong predictive value in the study population.